The impending loss of exclusivity for Eliquis (apixaban) is poised to become one of the most significant revenue-generating events in…
Read More

The impending loss of exclusivity for Eliquis (apixaban) is poised to become one of the most significant revenue-generating events in…
Read More
In a landmark study published on October 3 in the journal Nature Neuroscience, researchers from the Montefiore Einstein Comprehensive Cancer…
Read More